|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2014
gptkb:FDA
|
|
gptkbp:casnumber
|
53179-13-8
|
|
gptkbp:chemical_formula
|
C12 H11 N3 O
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
treatment of lung fibrosis
|
|
gptkbp:composed_by
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
liver impairment
|
|
gptkbp:developed_by
|
gptkb:Inter_Mune
|
|
gptkbp:discovery_year
|
gptkb:2000
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:tablet
gptkb:capsule
oral suspension
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
pirfenidone
|
|
gptkbp:interacts_with
|
gptkb:warfarin
other antifibrotic agents
|
|
gptkbp:invention
|
patented
|
|
gptkbp:lifespan
|
approximately 24 hours
|
|
gptkbp:marketed_as
|
gptkb:Esbriet
|
|
gptkbp:mechanism_of_action
|
anti-fibrotic
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:provides_guidance_on
|
recommended for IPF patients
|
|
gptkbp:research_areas
|
clinical trials
drug development
pharmacology
anti-inflammatory drugs
drug safety
respiratory diseases
chronic lung diseases
pulmonary medicine
anti-fibrotic drugs
fibrosis treatment
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
gptkb:anemia
fatigue
headache
muscle pain
nausea
weight loss
diarrhea
rash
insomnia
hypersensitivity reactions
elevated liver enzymes
liver function abnormalities
|
|
gptkbp:targets
|
inflammatory cytokines
fibroblast proliferation
extracellular matrix deposition
|
|
gptkbp:used_for
|
gptkb:idiopathic_pulmonary_fibrosis
|
|
gptkbp:bfsParent
|
gptkb:Esbriet
|
|
gptkbp:bfsLayer
|
7
|